{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:55:01Z","timestamp":1793829301497,"version":"4.6.1"},"reference-count":102,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UID\/BIO\/04469\/2013"],"award-info":[{"award-number":["UID\/BIO\/04469\/2013"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/93078\/2013"],"award-info":[{"award-number":["SFRH\/BD\/93078\/2013"]}]},{"name":"COMPETE 2020","award":["POCI-01-0145-FEDER-006684"],"award-info":[{"award-number":["POCI-01-0145-FEDER-006684"]}]},{"name":"BioTecNorte operation","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background: candidiasis is the primary fungal infection encountered in patients undergoing prolonged hospitalization, and the fourth leading cause of nosocomial bloodstream infections. One of the most important Candida spp. virulence factors is the ability to form biofilms, which are extremely refractory to antimicrobial therapy and very difficult to treat with the traditional antifungal therapies. It is known that the prophylaxis or treatment of a systemic candidiasis are recurrently taken without considering the possibility of a Candida spp. biofilm-related infections. Therefore, it is important to assess the effectiveness of the available drugs and which formulations have the best performance in these specific infections. Methods: 24-h-biofilms of four Candida spp. and their response to two amphotericin B (AmB) pharmaceutical formulations (liposomal and deoxycholate) were evaluated. Results: generally, Candida glabrata was the less susceptible yeast species to both AmBs. MBECs revealed that it is therapeutically more appealing to use AmB-L than AmB-Deox for all Candida spp. biofilms, since none of the determined concentrations of AmB-L reached 10% of the maximum daily dose, but both formulations showed a very good capacity in the biomass reduction. Conclusions: the liposomal formulation presents better performance in the eradication of the biofilm cells for all the species in comparison with the deoxycholate formulation.<\/jats:p>","DOI":"10.3390\/pathogens6040062","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T12:30:16Z","timestamp":1512131416000},"page":"62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp."],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-2230","authenticated-orcid":false,"given":"C\u00e9lia","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Centre of Biological Engineering (CEB), LIBRO\u2014Laborat\u00f3rio de Investiga\u00e7\u00e3o em Biofilmes Ros\u00e1rio Oliveira, University of Minho, 4710-057 Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0317-4877","authenticated-orcid":false,"given":"Mariana","family":"Henriques","sequence":"additional","affiliation":[{"name":"Centre of Biological Engineering (CEB), LIBRO\u2014Laborat\u00f3rio de Investiga\u00e7\u00e3o em Biofilmes Ros\u00e1rio Oliveira, University of Minho, 4710-057 Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rodrigues, C., Rodrigues, M., Silva, S., and Henriques, M. (2017). Candida glabrata Biofilms: How Far Have We Come?. J. Fungi, 3.","DOI":"10.3390\/jof3010011"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Silva, S., Rodrigues, C., Ara\u00fajo, D., Rodrigues, M., and Henriques, M. (2017). Candida Species Biofilms\u2019 Antifungal Resistance. J. Fungi, 3.","DOI":"10.3390\/jof3010008"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","article-title":"The changing face of epidemiology of invasive fungal disease in Europe","volume":"52","year":"2009","journal-title":"Mycoses"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/mmy\/myw026","article-title":"Probiotic yeast Saccharomyces boulardii (nom. nud.) modulates adhesive properties of Candida glabrata","volume":"54","author":"Zupan","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0966-842X(02)00002-1","article-title":"Candida biofilms and their role in infection","volume":"11","author":"Douglas","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/528521","article-title":"Fungal biofilm resistance","volume":"2012","author":"Ramage","year":"2012","journal-title":"Int. J. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.curtheres.2014.07.002","article-title":"Fluconazole Resistance Patterns in Candida Species that Colonize Women with HIV Infection","volume":"76","author":"Zhang","year":"2014","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.coph.2013.08.008","article-title":"Antifungal therapy with an emphasis on biofilms","volume":"13","author":"Pierce","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4155\/fmc.13.189","article-title":"Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms","volume":"6","author":"Delattin","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","article-title":"Amphotericin B","volume":"68","author":"Lemke","year":"2005","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920009788898019","article-title":"Amphotericin B and its new derivatives-mode of action","volume":"10","author":"Baginski","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4067\/S0716-10182014000500002","article-title":"Lipid formulations of amphotericin","volume":"31","author":"Botero","year":"2014","journal-title":"Rev. Chil. Infectol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1271\/bbb.110673","article-title":"Streptomyces nodosus host strains optimized for polyene glycosylation engineering","volume":"76","author":"Stephens","year":"2012","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF01575123","article-title":"Biopharmaceutical aspects of lipid formulations of amphotericin B","volume":"16","author":"Storm","year":"1997","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_17","first-page":"17","article-title":"Anfotericina B forma liposomal: Un perfil farmacocin\u00e9tico exclusivo. Una historia incabada","volume":"25","author":"Azanza","year":"2012","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_18","first-page":"S5","article-title":"Liposomal drug delivery system from laboratory to clinic","volume":"51","author":"Kshirsagar","year":"2005","journal-title":"J. Postgrad. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","article-title":"Amphotericin B lipid preparations: What are the differences?","volume":"14","author":"Proffitt","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1517\/14656566.1.3.475","article-title":"Amphotericin B colloidal dispersion","volume":"1","author":"Patel","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mycmed.2005.06.005","article-title":"Lipid formulations of amphotericin B: Where are we today?","volume":"14","author":"Antoniadou","year":"2005","journal-title":"J. Mycol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00005792-199707000-00004","article-title":"Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature","volume":"76","author":"Berenguer","year":"1997","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years\u2019 experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/16.1.118","article-title":"Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts","volume":"16","author":"Tritz","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1099\/jmm.0.075507-0","article-title":"In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates","volume":"63","author":"Montagna","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","article-title":"Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections","volume":"69","author":"Moen","year":"2009","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s10096-014-2194-8","article-title":"Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey","volume":"33","author":"Ricardo","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/500939","article-title":"Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill Patient","volume":"42","author":"Arendrup","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11046-014-9727-7","article-title":"In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation","volume":"177","author":"Gospodarek","year":"2014","journal-title":"Mycopathologia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/13693786.2010.503195","article-title":"Species distribution and in vitro antifungal susceptibility of clinical Candida isolates from a university hospital in Turkey over a 5-year period","volume":"49","author":"Kiraz","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiac.2015.05.007","article-title":"In vitro efficacy of liposomal amphotericin B, micafungin and fluconazole against non-albicans Candida species biofilms","volume":"21","author":"Kawai","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11046-015-9916-z","article-title":"Species Distribution, Virulence Factors, and Antifungal Susceptibility Among Candida parapsilosis Complex Isolates Recovered from Clinical Specimens","volume":"180","author":"Silva","year":"2015","journal-title":"Mycopathologia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","first-page":"266","article-title":"Identification of Azole Resistance Markers in Clinical Isolates of Candida tropicalis Using cDNA-AFLP Method","volume":"272","author":"Kanani","year":"2015","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jgar.2016.03.003","article-title":"Amino acid substitutions in Erg11p of azole-resistant Candida glabrata: Possible effective substitutions and homology modelling","volume":"5","author":"Nabili","year":"2016","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.idc.2015.10.013","article-title":"Invasive Candidiasis","volume":"30","author":"McCarty","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"101","author":"Pfaller","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: Mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1128\/AAC.03570-14","article-title":"The Production of Reactive Oxygen Species Is a Universal Action Mechanism of Amphotericin B against Pathogenic Yeasts and Contributes to the Fungicidal Effect of This Drug","volume":"58","author":"Roman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: Comparison of three amphotericin B preparations","volume":"52","author":"Linder","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: Time for a new \u201cgold standard\u201d","volume":"37","author":"Marr","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","article-title":"Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis","volume":"89","author":"Safdar","year":"2010","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Coenye, T., and Bjarnsholt, T. (2016). The complexity of microbial biofilm research\u2014An introduction to the 3rd Thematic Issue on Biofilms. Pathog. Dis., 74.","DOI":"10.1093\/femspd\/ftw053"},{"key":"ref_47","unstructured":"(2017, March 01). European Committee on Antimicrobial Susceptibility Testing Antifungal Agents Breakpoint Tables for Interpretation of MICs, Version 8.1. Available online: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Clinical_breakpoints\/Antifungal_breakpoints_v_8.1_March_2017.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.35.6.1208","article-title":"Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats","volume":"35","author":"Fielding","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jac\/44.3.397","article-title":"In Vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole","volume":"44","author":"Quinds","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/JCM.00937-08","article-title":"Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: Results of a 3-year (2004 to 2007) surveillance study","volume":"46","author":"Gonzalez","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1128\/AAC.01145-12","article-title":"Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2","volume":"56","author":"Hull","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1128\/AAC.06253-11","article-title":"Facultative sterol uptake in an ergosterol-deficient clinical isolate of candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B","volume":"56","author":"Hull","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/AAC.46.6.1723-1727.2002","article-title":"In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6, 970 Clinical Isolates of Candida spp.","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental Candida albicans Infection of the Central Nervous System","volume":"182","author":"Groll","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01975823","article-title":"Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B","volume":"10","author":"Anaissie","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_56","first-page":"22","article-title":"A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study","volume":"12","author":"Jessup","year":"2000","journal-title":"J. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.00662-08","article-title":"Activities of antifungal agents against yeasts and filamentous fungi: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"52","author":"Mayr","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1086\/429330","article-title":"Treatment of Candida infections with amphotericin B lipid complex","volume":"40","author":"Ito","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11046-015-9894-1","article-title":"Candida albicans Amphotericin B-Tolerant Persister Formation is Closely Related to Surface Adhesion","volume":"181","author":"Sun","year":"2016","journal-title":"Mycopathologia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13693780701487821","article-title":"Dormancy of Candida albicans cells in the presence of the polyene antibiotic amphotericin B: Simple demonstration by flow cytometry","volume":"45","author":"Boucherit","year":"2007","journal-title":"Med. Mycol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1128\/AAC.00684-06","article-title":"Candida albicans biofilms produce antifungal-tolerant persister cells","volume":"50","author":"LaFleur","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1128\/AAC.00860-09","article-title":"Patients with long-term oral carriage harbor high-persister mutants of Candida albicans","volume":"54","author":"LaFleur","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1128\/AAC.01473-07","article-title":"Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species","volume":"52","author":"Douglas","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1099\/jmm.0.015784-0","article-title":"Apoptosis in Candida biofilms exposed to amphotericin B","volume":"59","author":"Douglas","year":"2010","journal-title":"J. Med. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1128\/AAC.00280-11","article-title":"Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole","volume":"55","author":"Bink","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Dawson, C.C., Intapa, C., and Jabra-Rizk, M.A. (2011). \u201cPersisters\u201d: Survival at the cellular level. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002121"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Uppuluri, P., Chaturvedi, A.K., Srinivasan, A., Banerjee, M., Ramasubramaniam, A.K., K\u00f6hler, J.R., Kadosh, D., and Lopez-Ribot, J.L. (2010). Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog, 6.","DOI":"10.1371\/journal.ppat.1000828"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2672.2009.04634.x","article-title":"Exopolysaccharide analysis of biofilm-forming Candida albicans","volume":"109","author":"Lal","year":"2010","journal-title":"J. Appl. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/08927014.2014.886108","article-title":"Effects of fluconazole on Candida glabrata biofilms and its relationship with ABC transporter gene expression","volume":"30","author":"Fonseca","year":"2014","journal-title":"Biofouling"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1128\/AAC.39.9.2128","article-title":"Resistance of Candida albicans biofilms to antifungal agents in vitro","volume":"39","author":"Hawser","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/13693786.2011.580016","article-title":"Comparative analysis of Candida biofilm quantitation assays","volume":"50","author":"Taff","year":"2012","journal-title":"Med. Mycol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ajcp\/70.3.420","article-title":"Endocarditis caused by Torulopsis glabrata","volume":"70","author":"Heffner","year":"1978","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Tumbarello, M., Fiori, B., Trecarichi, E.M., Posteraro, P., Losito, A.R., de Luca, A., Sanguinetti, M., Fadda, G., Cauda, R., and Posteraro, B. (2012). Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033705"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Vila, T.V.M., and Rozental, S. (2016). Biofilm formation as a pathogenicity factor of medically important fungi. Fungal Pathogenicity, InTech.","DOI":"10.5772\/62768"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2005.06.020","article-title":"Candida albicans biofilms: More than filamentation","volume":"15","year":"2005","journal-title":"Curr. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02378-12","article-title":"Role of matrix \u03b2-1,3-glucan in antifungal resistance of non-albicans Candida biofilms","volume":"57","author":"Mitchell","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11046-015-9862-9","article-title":"Detection and Quantification of Fluconazole Within Candida glabrata Biofilms","volume":"179","author":"Rodrigues","year":"2015","journal-title":"Mycopathologia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"64","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","unstructured":"Astellas Pharma US, Inc. (2012). AmBisome (Amphotericin B) Liposome for Injection, Astellas Pharma US, Inc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1128\/AAC.00423-08","article-title":"A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata","volume":"52","author":"Vandeputte","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/AAC.01510-06","article-title":"Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth","volume":"51","author":"Vandeputte","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.01271-10","article-title":"Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice","volume":"55","author":"Ferrari","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.01141-06","article-title":"Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals","volume":"51","author":"Choi","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","article-title":"Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins","volume":"46","author":"Kuhn","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2015.02.021","article-title":"Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors","volume":"46","author":"Liao","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Luiz, R.L.F., Vila, T.V.M., de Mello, J.C.P., Nakamura, C.V., Rozental, S., and Ishida, K. (2015). Proanthocyanidins polymeric tannin from Stryphnodendron adstringens are active against Candida albicans biofilms. BMC Complement. Altern. Med., 15.","DOI":"10.1186\/s12906-015-0597-4"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mimet.2015.09.002","article-title":"Evaluation of baicalein, chitosan and usnic acid effect on Candida parapsilosis and Candida krusei biofilm using a Cellavista device","volume":"118","author":"Kvasnickova","year":"2015","journal-title":"J. Microbiol. Methods"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2015.03.019","article-title":"Induction of ROS generation by fluconazole in Candida glabrata: Activation of antioxidant enzymes and oxidative DNA damage","volume":"82","author":"Mahl","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1093\/jac\/dkw162","article-title":"Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms","volume":"71","author":"Escribano","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1099\/jmm.0.000042","article-title":"Patterns of candida biofilm on intrauterine devices","volume":"64","author":"Zahran","year":"2015","journal-title":"J. Med. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/mmy\/myu046","article-title":"Synergistic effect of amphotericin B and tyrosol on biofilm formed by Candida krusei and Candida tropicalis from intrauterine device users","volume":"52","author":"Shanmughapriya","year":"2014","journal-title":"Med. Mycol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/AAC.00057-14","article-title":"Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm candida species determined by microcalorimetry","volume":"58","author":"Maiolo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5578\/mb.24248","article-title":"Investigation of the correlation between biofilm forming ability of urinary Candida isolates with the use of urinary catheters and change of antifungal susceptibility in the presence of biofilm","volume":"50","author":"Aslan","year":"2016","journal-title":"Mikrobiyol. Buleni"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/pmic.200900611","article-title":"Proteomics of drug resistance in candida glabrata biofilms","volume":"10","author":"Seneviratne","year":"2010","journal-title":"Proteomics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/lam.12600","article-title":"Candida glabrata\u2019s recurrent infections: Biofilm formation during Amphotericin B treatment","volume":"63","author":"Rodrigues","year":"2016","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_96","first-page":"55","article-title":"The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms","volume":"23","author":"Ibrahim","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4161\/viru.27373","article-title":"ER stress response mechanisms in the pathogenic yeast Candida glabrata and their roles in virulence","volume":"5","author":"Miyazaki","year":"2014","journal-title":"Virulence"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1128\/AAC.00997-06","article-title":"A Small Subpopulation of Blastospores in Candida albicans Biofilms Exhibit Resistance to Amphotericin B Associated with Differential Regulation of Ergosterol and B-1,6-Glucan Pathway Genes","volume":"50","author":"Prasanna","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia\u2014Forming moulds","volume":"14","author":"Arendrup","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12281-012-0100-3","article-title":"EUCAST and CLSI: How to assess in vitro susceptibility and clinical resistance","volume":"6","year":"2012","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11046-017-0135-7","article-title":"The Effectiveness of Voriconazole in Therapy of Candida glabrata\u2019s Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression","volume":"182","author":"Rodrigues","year":"2017","journal-title":"Mycopathologia"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Rodrigues, C., and Henriques, M. (2017). Oral mucositis caused by Candida glabrata biofilms: Failure of the concomitant use of fluconazole and ascorbic acid. Ther. Adv. Infect. Dis., 4.","DOI":"10.1177\/2049936116684477"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/6\/4\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:52:10Z","timestamp":1760208730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/6\/4\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":102,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["pathogens6040062"],"URL":"https:\/\/doi.org\/10.3390\/pathogens6040062","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}